GPSVFPLAPSSK-¹³C₆,¹⁵N₂ TFA 

GPSVFPLAPSSK-¹³C₆,¹⁵N₂ TFA is the ¹³C- and ¹⁵N-labeled GPSVFPLAPSSK. GPSVFPLAPSSK is an IgG1 signature peptide of anti-SARS-CoV-2 antibodies. GPSVFPLAPSSK can be used for the quantification of the specific isolation of anti-SARS-CoV-2 antibodies^[1][2].

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1194.30 (free base)

C₄₉¹³C₆H₈₇N₁₁¹⁵N₂O₁₆.xC₂HF₃O₂

Gly-Pro-Ser-Val-Phe-Pro-Leu-Ala-Pro-Ser-Ser-{Lys-13C6,15N2}

GPSVFPLAPSS-{Lys-13C6,15N2}

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. de Jong KAM, et al. Quantification of anti-SARS-CoV-2 antibodies in human serum with LC-QTOF-MS. J Pharm Biomed Anal. 2021 Oct 25;205:114319.  [Content Brief]

  [2]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-226.  [Content Brief]